Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dorival Mendes Rodrigues-Junior, Maria Fernanda de Andrade Pelarin, Helena Bonciani Nader, André Luiz Vettore & Maria Aparecida Silva Pinhal. (2021) MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase. OncoTargets and Therapy 14, pages 455-467.
Read now
Read now
Jamal Bamoulid, Oliver Staeck, Fabian Halleck, Michael Dürr, Alexander Paliege, Nils Lachmann, Susanne Brakemeier, Lutz Liefeldt & Klemens Budde. (2015) Advances in pharmacotherapy to treat kidney transplant rejection. Expert Opinion on Pharmacotherapy 16:11, pages 1627-1648.
Read now
Read now
Articles from other publishers (13)
Michael Dolph, Gabriel Tremblay, Adrienne M Gilligan & Hoyee Leong. (2021) Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma. Journal of Health Economics and Outcomes Research 8:2.
Crossref
Crossref
Michael Dolph, Gabriel Tremblay, Adrienne M Gilligan & Hoyee Leong. (2021) Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma. Journal of Health Economics and Outcomes Research 8:2, pages 26-35.
Crossref
Crossref
Catarina Sofia Henriques de Jesus, Teodor Adrian Enache & Victor Constantin Diculescu. (2020) Charge transfer reaction mechanisms of epoxyketone and boronated peptides at glassy carbon and boron doped diamond electrodes. Journal of Electroanalytical Chemistry 878, pages 114733.
Crossref
Crossref
Sebastian Grosicki, Maryana Simonova, Ivan Spicka, Ludek Pour, Iryrna Kriachok, Maria Gavriatopoulou, Halyna Pylypenko, Holger W Auner, Xavier Leleu, Vadim Doronin, Ganna Usenko, Nizar J Bahlis, Roman Hajek, Reuben Benjamin, Tuphan K Dolai, Dinesh K Sinha, Christopher P Venner, Mamta Garg, Mercedes Gironella, Artur Jurczyszyn, Pawel Robak, Monica Galli, Craig Wallington-Beddoe, Atanas Radinoff, Galina Salogub, Don A Stevens, Supratik Basu, Anna M Liberati, Hang Quach, Vesselina S Goranova-Marinova, Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Phillipe Moreau, Moshe Levy, Darrell White, Moshe E Gatt, Thierry Facon, Maria V Mateos, Michele Cavo, Donna Reece, Larry D AndersonJrJr, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita A Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G Kauffman, Meletios A Dimopoulos, Paul G Richardson & Sosana Delimpasi. (2020) Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. The Lancet 396:10262, pages 1563-1573.
Crossref
Crossref
Tiffany Li, Hannah C. Timmins, Tracy King, Matthew C. Kiernan, David Goldstein & Susanna B. Park. (2020) Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. Hematological Oncology 38:3, pages 229-243.
Crossref
Crossref
Jianbiao Zhou & Wee-Joo Chng. (2019) Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World Journal of Clinical Oncology 10:9, pages 303-306.
Crossref
Crossref
Dorival Rodrigues‑Junior, Tha�s Biassi, Gabriela de Albuquerque, Viviane Carlin, Marcus Buri, Joel Machado‑Junior & Andre Vettore. (2019) Downregulation of DCC sensitizes multiple myeloma cells to bortezomib treatment. Molecular Medicine Reports.
Crossref
Crossref
Da Gao, Ai‐e Lv, Hui‐Ping Li, Dong‐Hai Han & Ya‐Peng Zhang. (2017) LncRNA MALAT‐1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma. Journal of Cellular Biochemistry 118:10, pages 3341-3348.
Crossref
Crossref
Zammam Areeb, Stanley S. Stylli, Thomas M. B. Ware, Nicole C. Harris, Lipi Shukla, Ramin Shayan, Lucia Paradiso, Bo Li, Andrew P. Morokoff, Andrew H. Kaye & Rodney B. Luwor. (2016) Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. Medical Oncology 33:5.
Crossref
Crossref
Jie Zhang, Bing Li, Haixia Wu, Jiayao Ou, Rongbin Wei, Junjun Liu, Wenping Cai, Xiaodong Liu, Shouliang Zhao, Jianhua Yang, Lili Zhou, Shangfeng Liu & Aibin Liang. (2015) Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi. Tumor Biology 37:1, pages 531-539.
Crossref
Crossref
Cristina Meregalli. (2015) An Overview of Bortezomib-Induced Neurotoxicity. Toxics 3:3, pages 294-303.
Crossref
Crossref
Noah Merin & Kevin Kelly. (2014) Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma. Pharmaceuticals 8:1, pages 1-20.
Crossref
Crossref
Samuel M. Shin, Robert J. Chouake, Nicholas J. Sanfilippo, Timothy B. Rapp, Perry Cook, Silvia C. Formenti, Amitabha Mazumder & Joshua S. Silverman. (2014) Feasibility and Efficacy of Local Radiotherapy With Concurrent Novel Agents in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 14:6, pages 480-484.
Crossref
Crossref